Presbyterian Health Foundation (PHF) Bridge Grant Program – Request For Applications
- Cycle II PHF Bridge Grant Program Deadline: August 4, 2021
- Cycle III PHF Bridge Grant Program Deadline: November 10, 2021
The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program can provide funding for up to $75,000 for one year. Guidelines and Application Form are attached for both cycles or can be found here. If you have any questions, please email ORA4PHF@ouhsc.edu.
Bridge (Cycle II)
Wednesday, August 4, 2021
Bridge (Cycle III)
Wednesday, November 10, 2021
Any OU Health Sciences Center (HSC) student is eligible to receive Sooner Heritage Scholarships with these caveats:
- A 2021-2022 FAFSA is on file with our office, and
- The Sooner Heritage Scholarship application must be completed (see instructions below), and
- Undergraduate students must be enrolled in at least six hours per semester to qualify, or graduate/professional students must be enrolled in at least five hours per semester.
- Sooner Heritage Scholarship funds are for Fall and Spring terms, but are not processed for the Summer term.
The Sooner Heritage application can be found by logging into your student Self-Service here. Navigate to the Student Center and you will find a link to the application on the right under Online Forms. You will receive an email confirming your application once you submit. If you have already applied for the scholarship, it will not let you apply a second time.
The deadline to apply is June 11, 2021.
NASA-NIH-BARDA-FDA-NCATS-NAID solicitation June & 8th Pre-Proposers Conference - Extended Longevity of 3D Tissues and Microphysiological Systems for Modeling of Acute and Chronic Exposures to Stressors (3DTANDMPS)
Proposals Due June 28, 2021. See attached document for additional information.
ORCID iD—Required for Some, Encouraged for All
ORCID helps connect you with your contributions to science over time and across changes of name, location, and institutional affiliation. ORCID’s goal is to provide automatic linkages, help people find information, simplify reporting and analysis, and save you from unnecessary data entry. If you will be supported by an NIH training (T), fellowship (F), education, or career development (K) award in fiscal year (FY) 2020, you must create an ORCID iD (Open Researcher and Contributor Identifier) and associate it with your eRA Commons Personal Profile. All researchers are encouraged to take the same steps, even though NIH does not require it for other award types. The Center for Faculty Excellence can help walk you through the process of 1) signing up for your ORCiD and populating your information fields, 2) signing up for your NCBI account and 3) creating your SciENcv. For additional information, please contact Clara Smith at firstname.lastname@example.org.
Oklahoma Center for the Advancement of Science and Technology (OCAST) Deadlines see the OTHER DEADLINES Section below.
Would you like assistance with your research, case study or QI project from an OU College of Medicine student? Medical students are eager to gain research experience and to help OU faculty and residents with their projects. Students are interested in paid or unpaid positions and available time varies by their year in the curriculum. Simply share some basic information regarding your project on the Student Research Opportunities Portal in order to have an interested student contact you. (https://com.ouhsc.edu/research-project?posting)
PLEASE NOTE: Change to OUHSC new NIH Other Support pages requirements.
OUHSC will not start implementing this policy internally until October 01, 2021 (previously July 1, 2021). Please keep in mind, that other institutions may have already implemented this policy and you may be required to use the new format for them before the OUHSC October 01, 2021 date.
Effective immediately, all Human Subject Research (HSR) activities including clinical trials are allowed to resume provided all OUHSC COVID-19 safety protocols can be met. It is expected that all personnel will adhere to the requirements in the OUHSC COVID-19 Response Plan.
If your current HSR protocol was temporarily halted due to the COVID-19 restrictions, the HRPP Office will update the study status of those protocols without any action required from you.
Also, in accordance with campus policy, our research laboratories* remain closed to K-12 students for shadowing, volunteer, and educational purposes, but open to visitors, undergraduates, graduates, and post-docs from any institution for those purposes, provided the following are observed by these individuals. The manager of the area where these individuals will be is responsible for compliance:
- individuals will be required to show proof of a negative COVID test (within past 48 hours) or documentation of COVID vaccination, if required based on screening results
- all individuals will complete the HSC online COVID-19 training module in OnPoint, using their HSC credentials
- all individuals (including students, faculty, staff, and volunteers) will comply with OU’s COVID-19 vaccine policy:
- those with patient-facing or research participant-facing responsibilities or who will be in patient care or human research participant settings must be vaccinated against COVID-19
- all other individuals will be strongly encouraged to be vaccinated against COVID-19
* all individuals will be informed that they must comply with and be given the link to the HSC COVID-19 Response Plan
*Rotations in clinical areas on campus and at OUMI are limited to OUHSC students, at least through July 2021. With these changes, we are retiring the Return to Research Plan and will refer to the OUHSC COVID Response Plan for COVID protocols. If you identify a deficiency caused by this action, please email email@example.com.
OK-INBRE REQUEST FOR APPLICATIONS FOR RESEARCH PROJECTS
The Oklahoma IDeA Network of Biomedical Research Excellence (OK-INBRE) is requesting applications for research projects from full-time, tenure track faculty (or equivalent) at the University of Oklahoma Health Sciences Center (OUHSC) or the Oklahoma Medical Research Foundation (OMRF). OK-INBRE will fund four Research Project Investigator (RPI) Awards with a start date of November 1, 2021 and an end date of April 30, 2024. Funding for awards is anticipated to be $100,000 in direct costs per year. Applications must align with one of the OK-INBRE research themes of 1) Cancer, 2) Developmental Biology, or 3) Infectious Diseases. The application deadline is 5pm on August 13, 2021. Please see the attached funding opportunity announcement for details. Information can also be found on the OK-INBRE website at Funding Opportunities for OUHSC and OMRF. Questions regarding this OK-INBRE opportunity can be sent to Dawn Hammon (firstname.lastname@example.org) or Darrin Akins (email@example.com).
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email firstname.lastname@example.org or email@example.com).
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in 1) oncology: tumor targeted, immuno-oncology, cancer vaccines; 2) internal medicine: obesity/cachexia, heart failure, diabetic/CKD, NASH/T2D; 3) inflammation and immunology: rheumatology, gastroenterology, medical derm; or 4) rare disease: cardiology, neuro-musc., metabolic, hematology. Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies. Proposal template available upon request (submission deadline 6/18/21).
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( firstname.lastname@example.org ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
Notice of Pre-Application Webinar for RFA-AR-21-015 and RFA-AR-21-016 (NOT-AR-21-017)
Notice of Pre-Application Webinar for NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed) (NOT-DK-21-021)
New Receipt Date and Change in Cost Match Requirement for Commercial Fishing Occupational Safety Training Project Grants (T03) (NOT-OH-21-009)
New Receipt Date and Change in Cost Match Requirement for Commercial Fishing Occupational Safety Research Cooperative Agreement (U01) (NOT-OH-21-010)
Notice Announcing Data Generation Projects for the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2) Other Transaction Opportunity Announcement (NOT-RM-21-029)
Notice of Correction to RFA-CA-20-031, Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed) (NOT-CA-21-082)
Notice of Early Termination of RFA-DA-22-002, "Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)" (NOT-DA-21-058)
Notice to Extend the Application Due Date for RFA-FD-21-030 - "Strategies that Support Global Food Safety (U01) Clinical Trial Not Allowed" (NOT-FD-21-015)
Notice of Change to the Instructions for Appendices in PAR-21-026 "Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32 - Clinical Trial Not Allowed)" (NOT-GM-21-040)
Notice of Change to the Instructions for Appendices in PAR-21-146 "Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)" (NOT-GM-21-041)
Notice of Change to the Instructions for Appendices in PAR-19-299 "Bridges to the Baccalaureate Research Training Program (T34)" (NOT-GM-21-042)
Notice of Change to the Instructions for Appendices in PAR-19-366 "Institutional Research and Academic Career Development Awards (IRACDA) (K12 - Independent Clinical Trial Not Allowed)" (NOT-GM-21-043)
Notice of Change to the Instructions for Appendices in PAR-20-066 "Postbaccalaureate Research Education Program (R25 - Independent Clinical Trial Not Allowed)" (NOT-GM-21-044)
Notice of Change to the Instructions for Appendices in PAR-20-213 "National Institute of General Medical Sciences Predoctoral Institutional Research Training Grant (T32 - Clinical Trial Not Allowed)" (NOT-GM-21-046)
Notice of Change to the Instructions for Appendices in PAR-21-025 "Initiative for Maximizing Student Development (IMSD) (T32 - Clinical Trial Not Allowed)" (NOT-GM-21-047)
Notice of Change to the Instructions for Appendices in PAR-21-147 "Maximizing Access to Research Careers (T34)" (NOT-GM-21-048)
Notice of Correction to Application Instructions and Revision of Due Date for RFA MD-21-007 "Centers for Multiple Chronic Diseases Associated with Health Disparities: Prevention, Treatment, and Management (P50 Clinical Trial Required)" (NOT-MD-21-024)
Notice of Correction to Key Dates of RFA-MH-21-230, "Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)" (NOT-MH-21-295)
Notice of Change in Application Type for BRAIN Initiative: Team-Research BRAIN Circuit Programs TeamBCP (NOT-NS-21-065)
Notice of Correction to Funding Opportunity Description for PAR-21-237 "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)" (NOT-NS-21-071)
Notice of Correction and the Change of the Receipt Date for PAR-21-125 Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed); PAR-21-126 High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed); PAR-21-127 Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) (NOT-OD-21-136)
Notice to Extend the Response Date for NOT-TR-21-027, RFI: Facilitating the Early Diagnosis and Equitable Delivery of Gene-Targeted Therapies to Individuals with Rare Diseases (NOT-TR-21-029)
Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed) (NOT-CA-21-081)
Notice of Intent to Publish a Funding Opportunity Announcement for SPARC Human Open Research Neural Engineering Technology (HORNET) Initiative (U41 Clinical Trial Optional) (NOT-RM-21-023)
Notice of Special Interest (NOSI): Reduction of Sudden Unexpected Infant Death and Sudden Infant Death Syndrome (NOT-HD-21-032)
Notice of Special Interest (NOSI): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional) (NOT-MD-21-020)
Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborative HIV/AIDS Research at NIMHD Research Centers in Minority Institutions (RCMI) (NOT-MD-21-023) https://grants.nih.gov/grants/guide/notice-files/NOT-MD-21-023.html
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional) (PA-21-232) – Deadline October 5, 2021 and February 5, 2022
NIA Postdoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F32 Clinical Trial Not Allowed) (PAR-21-217) - Deadline August 8, 2021
NIA Predoctoral Fellowship Award to Promote Diversity in Translational Research for AD/ADRD (F31)
(PAR-21-218) - Deadline August 8, 2021
NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) (PAR-21-220) - Deadline June 12, 2021
Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional) (PAR-21-230) - Deadline August 13, 2021 and July 13, 2022
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed) (RFA-DA-22-005) - Deadline October 14, 2021
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Clinical Trial Not Allowed) (RFA-DA-22-007) - Deadline October 14, 2021
Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional) (RFA-DA-22-012) - Deadline August 5, 2021
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required) (RFA-DA-22-024) – Deadline October 14, 2021
Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required) (RFA-DA-22-030) - Deadline October 14, 2021
Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required) (RFA-HL-22-010) – Deadline October 14, 2021 and February 11, 2022
Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed) (RFA-HL-22-011) - Deadline October 14, 2021 and February 11, 2022
Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01 Clinical Trial Optional) (RFA-MH-21-225) - Deadline August 27, 2021
Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 Clinical Trial Optional) (RFA-MH-21-226) – Deadline August 27, 2021
Diabetes, Research and Wellness Foundation – Research Grants – Deadline June 30, 2021 and December 30, 2021
Oklahoma Center for the Advancement of Science and Technology (OCAST) – Health Research Program Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time
OCAST – Health Research Postdoctoral Fellowship - Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time
OCAST – Oklahoma Applied Research Support (OARS) Program - Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time
OCAST – Intern Partnership Program - Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time